{"id":"W3157445152","doi":"10.1093/rheumatology/keab247.166","title":"P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial","year":2021,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Internal medicine; Rheumatoid arthritis; Clinical endpoint; Psoriatic arthritis; Adverse effect; Certolizumab pegol; Placebo; Psoriasis Area and Severity Index; Randomized controlled trial; Tolerability; Physical therapy; Adalimumab; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001830107,0.001541449,0.003173135,0.0003481612,0.0004313251,0.001280206,0.0006716919,0.001568469,0.007312944],"category_scores_gemma":[0.001480574,0.0005939124,0.002085618,0.0005175511,0.0009143092,0.0009083465,0.0003621061,0.002346191,0.001118635],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005013989,"about_ca_system_score_gemma":0.001279234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000426484,"about_ca_topic_score_gemma":0.001176835,"domain_scores_codex":[0.9994912,0.0002514595,0.00004347986,0.00008346187,0.00004854949,0.00008190223],"domain_scores_gemma":[0.9991087,0.0002407759,0.0002331858,0.0000533411,0.0000745706,0.0002893466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9772763,0.00378473,0.0007877048,0.001189627,0.001062808,0.00006559482,0.00004398241,0.0001946253,0.00176663,0.00008073149,0.00101777,0.0127295],"study_design_scores_gemma":[0.9450293,0.05198245,0.001369291,0.00004920255,0.0004481373,0.00006510712,0.00001871355,0.0002239653,0.0002211014,0.0000926496,0.0004901271,0.000009974068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9782536,0.01058473,0.0007590206,0.000884557,0.0006466221,0.004495464,0.001709807,0.0001498581,0.002516387],"genre_scores_gemma":[0.9840633,0.004015417,0.001078716,0.001208154,0.0007054098,0.004911952,0.001424176,0.00002541611,0.002567461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007312944,"threshold_uncertainty_score":0.02446425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02011007499670484,"score_gpt":0.274099614645735,"score_spread":0.2539895396490301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}